--- title: "CJC-1295 (DAC) | PepTracker Pro" description: "A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "CJC-1295 (DAC)", "description": "A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification.", "url": "https://peptrackerpro.com/peptides/cjc-1295-dac", "lastReviewed": "2026-05-27", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "CJC-1295 (DAC)", "item": "https://peptrackerpro.com/peptides/cjc-1295-dac" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People comparing DAC vs no-DAC variants of CJC-1295?", "acceptedAnswer": { "@type": "Answer", "text": "CJC-1295 (DAC) is a research peptide studied in preclinical models. A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification." } }, { "@type": "Question", "name": "Those researching long-acting GH secretagogues?", "acceptedAnswer": { "@type": "Answer", "text": "CJC-1295 (DAC) is a research peptide studied in preclinical models. A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification." } }, { "@type": "Question", "name": "Individuals exploring sustained GH elevation approaches?", "acceptedAnswer": { "@type": "Answer", "text": "CJC-1295 (DAC) is a research peptide studied in preclinical models. A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ CJC-1295 (DAC) **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # CJC-1295 (DAC) Medium Evidence A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification. Aliases CJC-1295 with DAC +1 more Evidence Medium Evidence Last Updated 2026-05-27 Reading Time 2 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Why Researchers Study It](#why-researchers-study) 3. [Proposed Mechanisms](#proposed-mechanisms) 4. [Evidence Snapshot](#evidence-snapshot) 5. [Commonly Discussed Benefits](#benefits) 6. [Safety & Cautions](#safety) 7. [Comparisons](#comparisons) 8. [Calculator Tools](#calculator) 9. [Citations](#citations) ## What It Is CJC-1295 with DAC (Drug Affinity Complex) is a synthetic GHRH analog that incorporates a maleimidopropionic acid linker enabling covalent binding to circulating albumin. This DAC modification extends the peptide's half-life from approximately 30 minutes (no-DAC) to 6–8 days, producing sustained GH and IGF-1 elevation rather than the pulsatile release pattern of the no-DAC version. In clinical studies, a single subcutaneous injection of CJC-1295 DAC increased mean GH concentrations by 2- to 10-fold for up to 6 days and raised IGF-1 levels by 1.5- to 3-fold for 9–11 days. A Phase II trial enrolling 56 healthy subjects confirmed dose-dependent, sustained elevations in both GH and IGF-1 with once-weekly dosing. The sustained GH elevation produced by the DAC formulation differs fundamentally from natural GH physiology, which relies on discrete pulsatile secretion. This non-pulsatile pattern has raised concerns about potential desensitization of GH receptors and disruption of the normal GH feedback axis with chronic use. Researchers who prefer physiological GH pulsatility typically favor the no-DAC version combined with ipamorelin. CJC-1295 DAC was placed on the FDA's Category 2 list in October 2023. As of May 2026, it remains restricted for 503B outsourcing facilities, though the 503A compounding nomination has been withdrawn. It is classified as a prohibited substance by WADA and is not FDA-approved for any indication. Also known as: CJC-1295 with DAC, Drug Affinity Complex CJC-1295 ## Why Researchers Study It CJC-1295 with DAC provides a sustained, non-pulsatile elevation of GH and IGF-1 over days rather than hours. This pharmacokinetic profile makes it a useful research tool for studying the effects of chronic GH elevation versus the pulsatile release pattern produced by the no-DAC variant. ## Proposed Mechanisms - Drug Affinity Complex binds serum albumin, extending half-life to 6–8 days - Sustained activation of GHRH receptors on pituitary somatotrophs - Produces continuous GH and IGF-1 elevation rather than pulsatile release - Less frequent dosing requirement compared to CJC-1295 (no DAC) or sermorelin ## Evidence Snapshot Medium Evidence Low Medium High ## Commonly Discussed Benefits [Muscle Growth](/benefits/muscle-growth)[Fat Loss](/benefits/fat-loss)[Recovery](/benefits/recovery)[Sleep](/benefits/sleep)[Anti-Aging](/benefits/anti-aging) Researching CJC-1295 (DAC) ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=cjc-1295-dac) ## Safety & Cautions - Sustained GH elevation may differ from physiological pulsatile release - May cause water retention and joint stiffness - Not FDA-approved - Should be discussed with a healthcare provider ## Comparisons See how CJC-1295 (DAC) compares to related peptides: [CJC-1295 (DAC) vs CJC-1295](/compare/cjc-1295-dac-vs-cjc-1295) [CJC-1295 (DAC) vs Ipamorelin](/compare/cjc-1295-dac-vs-ipamorelin) [CJC-1295 (DAC) vs Sermorelin](/compare/cjc-1295-dac-vs-sermorelin) [CJC-1295 (DAC) vs Tesamorelin](/compare/cjc-1295-dac-vs-tesamorelin) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Teichman SL. et al. — Prolonged stimulation of GH and IGF-I by CJC-1295. JCEM. 2006 [PubMed](https://pubmed.ncbi.nlm.nih.gov/16352683/) ### Keep researching in the app - Log CJC-1295 (DAC) to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=cjc-1295-dac) [Browse more peptides](/peptides) ## Related Peptides ### CJC-1295 Medium Evidence A growth hormone releasing hormone analog studied for stimulating growth hormone secretion. [Muscle Growth](/benefits/muscle-growth)[Fat Loss](/benefits/fat-loss)[Recovery](/benefits/recovery)[Sleep](/benefits/sleep)+1 more [View Details](/peptides/cjc-1295) [\+ Compare](/compare?select=cjc-1295)[](https://app.peptrackerpro.com/?add=cjc-1295) ### Ipamorelin Medium Evidence A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides. [Muscle Growth](/benefits/muscle-growth)[Fat Loss](/benefits/fat-loss)[Recovery](/benefits/recovery)[Sleep](/benefits/sleep)+1 more [View Details](/peptides/ipamorelin) [\+ Compare](/compare?select=ipamorelin)[](https://app.peptrackerpro.com/?add=ipamorelin) ### Sermorelin Medium Evidence A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment. [Muscle Growth](/benefits/muscle-growth)[Fat Loss](/benefits/fat-loss)[Sleep](/benefits/sleep)[Recovery](/benefits/recovery)+1 more [View Details](/peptides/sermorelin) [\+ Compare](/compare?select=sermorelin)[](https://app.peptrackerpro.com/?add=sermorelin) ### Tesamorelin High Evidence A GHRH analog FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. [Fat Loss](/benefits/fat-loss)[Muscle Growth](/benefits/muscle-growth)[Metabolism](/benefits/metabolism)[Anti-Aging](/benefits/anti-aging) [View Details](/peptides/tesamorelin) [\+ Compare](/compare?select=tesamorelin)[](https://app.peptrackerpro.com/?add=tesamorelin) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.